BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

K Korfi¹, M Smith¹, J Swan², TCP Somervaille³, N Dhomen¹ and R Marais*¹

B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological disease that kills ~50% of adult patients. With the exception of some BCR-ABL1+ patients who benefit from tyrosine kinase inhibitors, there are no effective targeted therapies for adult B-ALL patients and chemotherapy remains first-line therapy despite adverse side effects and poor efficacy. We show that, although the MEK/ERK pathway is activated in B-ALL cells driven by different oncogenes, MEK inhibition does not suppress B-ALL cell growth. However, MEK inhibition synergized with BCL-2/BCL-XL family inhibitors to suppress proliferation and induce apoptosis in B-ALL cells. We show that this synergism is mediated by the pro-apoptotic factor BIM, which is dephosphorylated as a result of MEK inhibition, allowing it to bind to and neutralize MCL-1, thereby enhancing BCL-2/BCL-XL inhibitor-induced cell death. This cooperative effect is observed in B-ALL cells driven by a range of genetic abnormalities and therefore has significant therapeutic potential.

Cell Death and Disease (2016) 7, e2177; doi:10.1038/cddis.2016.70; published online 7 April 2016

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the third most common adult leukemia. Childhood ALL has good outcomes with 5-year survival rates of ~90%, whereas prognosis in older patients (15–65 years; ~40% of cases) is worse, with ~50% of patients dying from their disease. B-cell ALL (B-ALL) is the most common ALL (~70% of cases), so this disease has a clear unmet clinical need.1,2 In addition to age, B-ALL outcome and response to therapy is determined by the genetic alterations that drive disease, with the BCR-ABL1 and MLL rearrangement being associated with particularly poor prognosis.3 Chemotherapy remains first-line treatment in childhood and adult B-ALL1 and is combined with tyrosine kinase inhibitors (TKIs) in BCR-ABL1+ cases,4 but despite increased survival from intensive chemotherapy regimens, short- and long-term adverse effects are major drawbacks and the presence of chemoresistant subclones limits responses.5 Thus there is an urgent need for novel targeted therapies with improved efficacy and reduced toxicity.

The RAS/RAF/MEK/ERK pathway regulates proliferation in haematological malignancies and is activated by mutant RAS or RAF, activated receptor tyrosine kinases such as KIT and FLT3, chromosomal translocations such as BCR-ABL1 or ETV6-PDGFR, or chemotherapeutic agents.6 Mutations in NRAS, KRAS, and the protein phosphatase PTPN11 are associated not only with relapse and poorer outcomes in childhood leukemia but also with increased sensitivity to MEK inhibitors (MEKi).7,8 Critically, this pathway regulates survival and apoptosis through ERK-mediated phosphorylation of apoptotic effectors such as BAD and BIM or transcriptional regulation of BCL-2 family genes.6,9,10

In this study, we investigated how MEK/ERK signaling regulates B-ALL proliferation and survival. We found that inhibition of this pathway primed B-ALL cells for death by BCL-2/BCL-XL inhibitors (BCL-2i) through a mechanism dependent on the pro-apoptotic protein BIM. Thus we reveal a synergistic interaction between two pro-survival pathways that has therapeutic potential in a range of B-ALL subtypes.

Results

MEK inhibition does not block B-ALL cell growth. The MEK/ERK pathway is activated downstream of driver oncogenes such as BCR-ABL1 and NRAS,6 and accordingly, we observed different levels of MEK/ERK pathway activation not only in six B-ALL cell lines expressing BCR-ABL1+ or NRASG12D but also in four cell lines driven by other oncogenes, including ETV6-PDGFRB, ETV6-RUNX1, and MLL-AF4, except RS4;11 cells, which demonstrated no MEK/ERK pathway activity (Figures 1a and b; Supplementary Figures S1a and b; Supplementary Table S1). We therefore investigated this pathway in B-ALL cell proliferation and survival. Surprisingly, even profound pathway inhibition by the small-molecule MEKi trametinib (Figure 1c) did not inhibit B-ALL cell growth (Figure 1d; Supplementary Figures S1c and d; Supplementary Table S2) and induced only modest apoptosis (Figure 1e).

Received 14.1.16; revised 22.2.16; accepted 29.2.16; Edited by M Diedenich
BCL-2 and BCL-XL attenuate the effects of MEK inhibition in B-ALL cells. Thus the MEK/ERK pathway was active in B-ALL cells but was not required for survival, so to investigate the mechanisms underlying these cells’ intrinsic resistance to MEKi, we examined BIM and BAD, because ERK phosphorylates these pro-apoptotic proteins, inhibiting...
their binding to the pro-survival BCL-2 family members and promoting cell survival.\textsuperscript{9,10} Trametinib did not block BAD phosphorylation on serine 75 (S75) in B-ALL cells (Supplementary Figure S2a), did not change BAD binding to BCL-2 or BCL-XL, and did not induce BAD binding to a third pro-survival protein, MCL-1 (Supplementary Figure S2b). In contrast, trametinib induced robust BIM dephosphorylation on S69 (Figure 1f), and although this did not affect BIM binding to BCL-2, it significantly increased BIM binding to MCL-1 in 697, BV173R, and SUP-B15 cells and to BCL-XL in BV173R and SUP-B15 cells (Figures 1g and h).

We were intrigued that, despite these changes, MEK inhibition did not induce profound apoptosis but noted that, compared with normal CD34\textsuperscript{+} hematopoietic cells, BCL2\textsuperscript{ and BCLX} (BCL2L1) were significantly upregulated in B-ALL cells (Figure 2a). Accordingly, BCL-2 depletion significantly reduced B-ALL cell survival, and BCL-XL depletion had a modest effect (Figure 2b). More importantly, trametinib cooperated with BCL-2 or BCL-XL depletion to further suppress viability in these cells (Figure 2b).

**MEKi and BCL-2i cooperate to induce B-ALL cell death.**

The data above implicated BCL-2 and BCL-XL in intrinsic resistance to MEKi, so we tested whether BCL-2i cooperated with MEKi to suppress B-ALL cell viability. UMI-77, a selective MCL-1 inhibitor did not reduce B-ALL cell viability either alone or in combination with trametinib (Supplementary Table S3; Supplementary Figure S3a). AT-101, which binds to BCL-2 and BCL-XL at 300–400 nM, also failed to reduce B-ALL cell viability alone or in combination with trametinib (Supplementary Table S3; Supplementary Figure S3b). Similarly, sabutoclax, which binds to BCL-2 and BCL-XL at ~300 nM reduced viability modestly by itself but failed to cooperate with trametinib to kill the cells (Supplementary Table S3; Supplementary Figure S3c).

In contrast, ABT-263,\textsuperscript{11} which binds to BCL-2 at 1 nM and BCL-XL at 0.5 nM (Supplementary Table S3), not only inhibited the growth of all three cell lines by itself but also synergized with trametinib to further inhibit cell growth (Figures 2c and d). Similarly, ABT-199,\textsuperscript{12} which binds to BCL-2 at 0.01 nM and BCL-XL at 48 nM (Supplementary Table S3), inhibited cell growth alone, and it cooperated with trametinib to further reduce cell viability (Figure 2c). Note that trametinib/ABT-263 and trametinib/ABT-199 combinations were more effective at reducing cell viability than the TKI nilotinib in BCR-ABL\textsuperscript{+} cells (Figure 2c). Furthermore, the loss of cell viability with ABT-263 and ABT-199 was linked to increased apoptosis, and these drugs cooperated with trametinib to significantly increase apoptosis in these cells (Supplementary Figure S4a). The death induced by the trametinib/ABT-263 combination was accompanied by loss of mitochondrial membrane potential, demonstrating that apoptosis was mitochondrially mediated (Supplementary Figure S4b). We conclude that trametinib cooperated with the potent BCL-2i ABT-199 and ABT-263 to induce B-ALL cell death.

**BIM mediates synergistic killing of B-ALL cells by MEKi and BCL-2i.**

We extended our findings to other B-ALL cell lines and found that ABT-263 reduced viability of these cells alone and synergized with trametinib to further suppress viability of BV173, SUP-B15R, DOHH2, NALM6, REH, and SEM cells (Figures 3a and b; Supplementary Figure S5; Supplementary Table S4), and we observed similar results with the ABT-199/trametinib combination (Supplementary Figures S6a–d; Supplementary Table S4). Overall, the trametinib/ABT-263 combination was more effective than single agents in 9/11 lines and the trametinib/ABT-199 combination was more effective than single agents in 6/11 lines, so we were intrigued that the combinations did not synergize to inhibit the growth of RS4;11 and SD1 cells (Figure 3c; Supplementary Figures S6c and e). As shown above, the MEK/ERK pathway is not active in RS4;11 cells (Supplementary Figures S1a and b) and this is a prerequisite for the cooperation between MEKi and BCL2i. However, SD1 cells presented high levels of MEK/ERK activity (Figure 1a) but intriguingly did not express BIM (Figures 3d and e) and BIM re-expression was sufficient to kill these cells (Figure 3f). This implicated BIM in the synergistic killing of B-ALL cells by trametinib and ABT-263, and accordingly, we show that when BIM was depleted, trametinib no longer synergized with ABT-263 to kill BV173R or 697 cells (Figures 3g and h; Supplementary Figures S7a and b).

These data showed that BIM mediated the synergistic killing of B-ALL cells by MEKi and BCL-2i, so we investigated the mechanism. Our data above showed that trametinib increased BIM binding to MCL-1 (Figures 1g and h), and we found that ABT-263 alone or in combination with trametinib further increased BIM binding to MCL-1 (Figures 3i and j; Supplementary Figures S7c and d). Moreover, we observed increased BIM levels in the presence of trametinib alone or in combination with ABT-263 (Figure 3k; Supplementary Figure S7e), which could be due to the increased stability of the dephosphorylated form.\textsuperscript{10} Importantly, the sensitivity of B-ALL cells to ABT-263 was negatively correlated with phospho-MEK activity in these cell lines.

---

**Figure 1** Trametinib primes B-ALL cells to apoptosis through BIM dephosphorylation. (a and b) Western blottings showing phospho-MEK (pMEK), total MEK (MEK1/2), phospho-ERK (pERK), total ERK (ERK1/2), and \(\alpha\)-tubulin (loading control) in five BCR-ABL\textsuperscript{+} B-ALL cell lines (a) and six BCR-ABL\textsuperscript{+} cell lines (b). The dotted line indicates where discontinuous sections of blots were joined. (c) Western blottings showing pERK and ERK1/2 (loading control) in B-ALL cells treated with trametinib (40 nM) at the indicated times. (d) Dose-response curves for trametinib (72 h) treatment of 697, BV173R, and SUP-B15 B-ALL cells. Cell viability (%) is relative to dimethyl sulfoxide (DMSO) control and A375 (BRAF\textsuperscript{V600E} melanoma) cells provide a positive control for sensitive cells. (e) Graphs represent apoptotic cells (%) after treatment with DMSO (control) or trametinib (40nM) at the indicated times. (f) Western blottings showing phospho-S69-BIM (pBIM) and total BIM (BIM\textsubscript{EL}) in BIM immunoprecipitates from 697, BV173R, and SUP-B15 cells treated with trametinib (40 nM) for the times indicated. (g) Western blottings showing BIM, BCL-2, BCL-XL, MCL-1, and \(\alpha\)-tubulin (loading control) in cell lysates and BIM co-IPs from 697, BV173R, and SUP-B15 cells treated with DMSO (control; D) or trametinib (40 nM; T) for 24 h. (h) Graphs represent normalized quantification of BIM co-IPs from triplicate experiments for samples shown in panel (g). Error bars in panels (d, e, and h): S.E.M. *P<0.05; **P<0.01.

**Cell Death and Disease**
endogenous levels of BIM and MCL-1 (Supplementary Figures S8a and b), and when MCL-1 was depleted, ABT-263 strongly inhibited B-ALL cell proliferation even in the absence of trametinib (Supplementary Figures S8c and d). This suggested that the increase in BIM protein and its interaction with MCL-1 in the presence of both MEKi and BCL-2i, neutralized MCL-1, a mechanism that explains the synergistic effect observed between trametinib and ABT-263 in these cells.

**Figure 2** MEKi and BCL-2i synergize to kill B-ALL cells. (a) Scatter dot plot showing mRNA expression for BCL2, BCLXL, and MCL1 relative to housekeeping gene control in the 11 B-ALL cell lines (Supplementary Table S1) and normal primary CD34+ cells. Error bars: mean with 95% confidence intervals. **P < 0.01; NS, not significant. (b) Graphs showing cell viability (%) in 697, BV173R, and SUP-B15 cells transfected with control siRNA (siCtl), BCL-2 (siBCL-2), or BCL-XL (siBCL-XL) siRNAs and treated with dimethyl sulfoxide (DMSO; control; D) or trametinib (40nM; T) for 72 h. The western blottings below the graphs show knockdown efficacy. (c) Graphs showing cell viability after 72 h at 200 nM (697, BV173R cells) or 40 nM (SUP-B15 cells) ABT-263 or ABT-199 with or without 40 nM trametinib as indicated. BCR-ABL1+ cells were also treated with nilotinib (1 μM). Results are relative cell viability (%) to DMSO controls. Error bars in panels (b and c): S.E.M. *P < 0.05; **P < 0.01. (d) Isobolograms for trametinib/ABT-263 combinations in 697, BV173R, and SUP-B15 cells. Crosses on x and y axes indicate the IC50 values for each compound. Blue dots show the concentrations of the single drugs that lead to 50% inhibition in cell viability for the given combination ratios. Combination indices (CI) for the combination drug concentrations in panel (c) are also indicated (CI < 1 = synergism).

MEKi and BCL-2i cooperate to kill primary B-ALL cells and to delay the onset of B-ALL in vivo. Next we investigated whether MEKi and BCL-2i combinations could also kill freshly isolated cells from B-ALL patients (Supplementary Table S5, Figure 4a). At clinically achievable doses, trametinib and ABT-263 reduced the viability of undifferentiated CD34+/CD19+ cells purified from peripheral blood mononucleated cells of five B-ALL patients, but more importantly, these agents cooperated to further reduce cell viability in these samples.
viability in these cells (Figure 4a). As a control, we showed that trametinib and ABT-263 had a negligible effect on normal CD34+ cell viability from two non-ALL individuals (Figure 4b), showing that this combination specifically targeted the leukemic cells while sparing normal hematopoietic cells. Finally, 697 cells were inoculated into non-obese diabetic scid gamma (NSG) mice, and the mice were treated with trametinib, ABT-263, or the combination for 3 weeks. Mice were killed at the onset of leukemia, manifested by ill health. We observed a small increase in survival with trametinib and a more substantial survival advantage with ABT-263, but critically these compounds cooperated to give a significant if modest increase in survival compared with the single-agent treatments (Figure 4c). Furthermore, trametinib and ABT-263 alone reduced the bone marrow leukemic cell burden by ~40% (P<0.05) compared with controls, but together, these agents reduced the leukemic cell burden in the bone marrow by ~60% (P<0.001; Figure 4d).

Discussion
This study demonstrates that MEKi plus BCL-2i is a promising drug combination in B-ALL cells. Recent studies suggested that only leukemias with mutations in RAS could benefit from MEKi therapy,7,13 but we showed that this pathway was activated in B-ALL cell lines driven by a range of genetic aberrations. We showed that inhibition of ERK resulted in dephosphorylation of the pro-apoptotic protein BIMEL, an important regulator of apoptosis in normal and malignant B cells, and a tumor suppressor in B-cell malignancies.14 It has been reported that BIM phosphorylation by ERK1/2 increased cell survival through reduced BIM binding to pro-survival proteins, including BCL-XL and MCL-1, and by increased BIM degradation.10,15 Accordingly, we showed that trametinib caused BIM dephosphorylation, resulting in upregulation of BIM protein and its binding to MCL-1, consistent with a recent study in chronic lymphocytic leukemia (CLL) showing that CLL cells were MCL-1-dependent and phosphorylated BIM was unable to interact with MCL-1 to induce apoptosis.16 However, despite priming B-ALL cells for apoptosis, trametinib only modestly affected their viability, suggesting that BIM dephosphorylation alone was insufficient to overcome pro-survival signals. Accordingly, the pro-survival genes BCL2 and BCLX were elevated in B-ALL cells compared with normal CD34+ cells. Upregulation of antiapoptotic proteins has been reported in some hematological malignancies.17,18 stimulating the development of potent BCL-2i.11,12 Importantly, it was reported that BCL-2 overexpression in lymphoid malignancies inhibited apoptosis through BIM sequestration19,20 and that BCL-2i induced apoptosis by disrupting the BCL-2/ BIM complex.

We showed that B-ALL cells demonstrate a range of sensitivities to ABT-199 and ABT-263, although complete loss of cell viability was not seen at clinically achievable doses. However, the cells could be killed when BCL-2i were combined with MEKi or when MCL-1 was depleted. Thus, in accordance with previous studies,21,22 we showed that intrinsic resistance of B-ALL cells to BCL-2i was mediated by MCL-1 and that the pro-survival effects of MCL-1 were overcome by BIM, which is phosphorylated and inactivated downstream of MEK/ERK. Previous studies showed that MEKi and BCL-2i cooperated to inhibit the growth of KRAS and BRAF mutant solid tumors.23,24 In those cases, MEK appeared to be the primary growth inhibitor, and BCL-2i enhanced the effect. However, we showed here that MEKi had a modest effect in B-ALL cells, but MEK inhibition sensitized the cells to BCL-2i through a MEK/ERK signaling-dependent mechanism mediated by BIM.

Thus we posit that the mechanism by which MEKi and BCL-2i cooperated to kill B-ALL cells was that MEK inhibition caused BIM dephosphorylation and upregulation at the protein level, allowing BIM to bind to and neutralize MCL-1, removing one survival signal. The concomitant inhibition of BCL-2 and BCL-XL removed the other survival signals, leading to cell death. Importantly, this cooperative effect occurred in B-ALL cells driven by a range of genetic abnormalities. We validated our findings in primary CD34+ CD19+ B-ALL cells at clinically achievable doses for both drugs while demonstrating that the combination spared normal CD34+ cells. Additionally, as the effect was mediated by BIM, the expression of this protein could serve as a convenient biomarker to stratify patients for this combination therapy. Our findings provide further insights into B-ALL cell biology and survival mechanisms and identify MEK and BCL-2/BCL-XL as targets that could be exploited for effective management of this disease.

Materials and Methods
Cell culture. For cell lines and their driver oncogenes, see Supplementary Table S1. BV173, BV173R, 697, and SD1 cells were cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Life Technologies, Paisley, UK). DOHH2, NALM6, REH, and SEM cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. SUP-B15 and SUP-B15R cells were cultured in McCoy’s 5A medium (Life Technologies) supplemented with 20% FBS and 1% penicillin/streptomycin. RS4;11 cells cultured in α-MEM medium (Life Technologies) supplemented with 10% FBS and 1% penicillin/streptomycin.

Primary CD34+ ALL and normal cells were cultured in IMDM medium (Life Technologies) supplemented with 25% BIT (bovine serum albumin/insulin/transferrin; StemCell Technologies, Vancouver, BC, Canada), L-glutamine, penicillin/streptomycin, and 125 μM 2-mercaptoethanol (Life Technologies). ALL CD34+ cells were cultured in the presence of FL3-ligand (100 ng/ml), IL-7 (100 ng/ml), and SCF (100 ng/ml), as described.25 Normal CD34+ cells were cultured in a five growth factor cocktail containing FL3-ligand (100 ng/ml), G-CSF (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), and SCF (100 ng/ml) (all growth factors are from PeproTech, Rocky Hill, NJ, USA).

Primary cells from patient samples. Peripheral blood from B-ALL patients was collected at diagnosis following informed consent and ethical approval from the scientific sub-committee of the Manchester Cancer Research Centre Tissue Biobank (07/H1003/161+5) and in compliance with the ethical and legal framework of the Declaration of Helsinki and the UK’s Human Tissue Act, 2004. Normal mobilized CD34+ cells surplus to requirements were from patients undergoing chemotherapy and autologous transplantation, and their use was authorized by the Salford and Trafford Research Ethics Committee (08/H1004/114) for samples collected since 2006 and following written informed consent of donors. Mononuclear cells were isolated from peripheral blood by Ficoll separation. CD34+ cell enrichment was by AutoMACS magnetic column separation (Miltenyi Biotec, Bergisch Gladbach, Germany) using the CD34 Human Microbead Kits (Miltenyi Biotec). CD34+ cells from B-ALL samples were >90% CD19+ by flow cytometry (anti-human CD19 PE, eBioscience, San Diego, CA, USA). For
clinical information and genetic abnormalities in patient samples, see Supplementary Table S5.

Reagents (inhibitors, siRNAs, and plasmids). Stock solutions (10 mM) of trametinib, ABT-199, ABT-263, AT-101, sabutoclax, and UMI-77 (Selleckchem, Houston, TX, USA) were prepared in DMSO and stored at −80 °C. Appropriate concentrations of each drug were prepared in DMSO prior to use. Cell lines were transfected with siRNAs to BCL-2 (ON-TARGETplus Human BCL2 SMARTpool; Dharmacon, Lafayette, CO, USA), BCL-XL (Hs_BCL2L1_2, QIAGEN, Hilden, Germany), MCL-1 (Hs_MCL1_6, QIAGEN), BIM (Hs_BCL2L11_5, QIAGEN), and BAD (Hs_BAD_3, QIAGEN) using 4D-Nucleofector system (Lonza, Basel, Switzerland). AllStars Negative Control siRNA (QIAGEN) was the negative control. The BIM-GFP expression plasmid was constructed by cloning the human BIMEL cDNA (BCL2L11-001, ENST00000393256) into a pMCEF vector and moving the
BamHI and AgeI restriction fragment into the pEGFP-N1 vector. The plasmid was transfected into SD1 cells using 40-Nucleofactor system (Lonza) and GFP⁺ cells were sorted by flow cytometry after 48 h.

Immunoprecipitation and immunoblot assays. Cell lysates were prepared using cell lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na₃VO₄, 1 μg/ml leupeptin; Cell Signaling, Danvers, MA, USA) with protease inhibitor cocktail and phosphatase inhibitor cocktail 3 (Sigma Aldrich, St. Louis, MO, USA). For co-immunoprecipitation (co-IP), cell extracts were prepared in CHAPS lysis buffer (20 mM Tris-HCl (pH 7.5), 137 mM NaCl, 1% CHAPS, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl₂, protease inhibitor cocktail, and phosphatase inhibitor cocktail 3) as described. Protein extracts were immunoprecipitated with anti-BIM (C34C5; Cell Signaling) and anti-BAD (C-7; Santa Cruz Biotechnology, Dallas, TX, USA) at 4 °C for 2 h. Immunoprecipitates were captured by 50 μl of protein G-agarose beads in CHAPS lysis buffer (Roche, Basel, Switzerland) at 4 °C for 3 h. Immunoprecipitates were recovered by centrifugation, washed three times in CHAPS buffer, and eluted in boiling NuPAGE LDS Sample Buffer and NuPAGE Sample Reducing Agent (Life Technologies). Immunoprecipitates and cell lysates (40 μg of protein) were separated by SDS-PAGE on NuPAGE Bis-Tris gels (Life Technologies). Immunoblots were performed with antibodies from Cell Signaling (BAX, BCL-XL, BIM, phosphoSer69-BIM, ERK1/2, MEK1/2, and phosphoSer217/221-ERK1-MEK), Santa Cruz (BCL-2 and BAD), Sigma-Aldrich (MCL-1, diphosphorylated ERK1/2, and α-tubulin), and Abcam (Cambridge, UK; phosphoSer112-BAD), probed by fluorescence secondary antibodies (Li-Cor, Lincoln, NE, USA) and analyzed on an Odyssey CLx infrared imaging system (Li-Cor). Densitometry analyses of western blotting bands were performed with antibodies from Cell Signaling (BAX, BCL-2, BCL-5, MCL-1, and phosphoSer112-BAD). Protein bands were quantified using Odyssey software (Li-Cor). All experiments were performed in triplicate.

Figure 3

BIM mediates the synergism between trametinib and ABT-263. (a) Graphs showing cell viability after 72 h at 200 nM ABT-263 with or without 40 nM trametinib in BCR-ABL⁺ cells (BV173, SUP-B15R) as indicated. Nilotinib is used at 1 μM. (b) Graphs showing cell viability after 72 h at 200 nM DOHH2 (DOHH2, REH, SEM cells) or 1 μM NALM6 cells) ABT-263 with or without 40 nM trametinib as indicated. (c) Graphs showing viability of SD1 cells after 72 h at 1 μM ABT-263 with or without 40 nM trametinib as indicated. Nilotinib is used at 1 μM. (d) Scatter dot plot showing BIM (BCL2L1) mRNA expression relative to housekeeping gene control in the 11 B-ALL cell lines. Error bars: mean with 95% confidence intervals. (e) Western blotting showing BIM and α-tubulin (loading control) expression in the B-ALL cells. (f) Graph displays (%) cell viability of SD1 cells 72 h after BIM-GFP transfection relative to GFP-transfected cells. The analysis was performed on cells selected for GFP expression by fluorescence-activated cell sorting. (g) Graphs showing BV173R cell viability 72 h after leukemia-free survival of mice inoculated with 697 cells and treated with vehicle, trametinib (0.15 mg/Kg), ABT-263 (100 mg/Kg), or trametinib (0.15 mg/Kg) plus ABT-263 (100 mg/Kg) for 3 weeks. (h) Scatter dot plot showing human CD19⁺ cells (%) measured by flow cytometry in the bone marrow of the mice at death in each treatment arm shown in panel (c). Error bars: mean with 95% confidence intervals. *P < 0.05; **P < 0.01; NS, not significant.
performed on Image Studio Life (Li-Cor). For BIM co-IP assays, normalized IP fold changes were calculated from band densitometries for BIM and its interacting proteins as follows:

\[
\begin{align*}
&\text{Interacting protein}_{\text{treatment}} - \text{Interacting protein}_{\text{DMSO}} \\
&\text{BIM}_{\text{treatment}} - \text{BIM}_{\text{DMSO}} \\
&\text{BIM}_{\text{treatment}} - \text{BIM}_{\text{DMSO}}
\end{align*}
\]

Cell viability assays. Cell lines were seeded at 1 x 10^4–2 x 10^5 cells/well and primary cells were seeded at 5 x 10^4 cells/well in 96-well plates and treated with DMSO (control) or small-molecule inhibitors for 72 h at 37 °C and 5% CO2. Cell proliferation and viability was measured by a methanethiosulfonate-based assay (CellTitre 96 Aqueous One Solution; Promega, Madison, WI, USA). Results were reported as the percentage of viability for cell lines or viability for primary cells relative to DMSO controls, and the S.E.M. was calculated from triplicates. The combined effect of trametinib and ABT-263 in fixed ratio combinations was quantified by the Chou–Talalay method.27

Apoptosis assays. The percentage of apoptotic cells in the presence or absence of small-molecule inhibitors was determined using 7-AAD (7-aminoactinomycin D) and PE annexin V probes (BD Biosciences, Franklin Lakes, NJ, USA) on a BD Accuri C6 flow cytometer (BD Biosciences). Results were reported as the average percentage of annexin V+ cells, and the S.E.M. was calculated from triplicates.

Mitochondrial membrane potential was determined 24 h posttreatment with DMSO or small-molecule inhibitors using a TMRE (tetramethylrhodamine, ethyl ester) Mitochondrial Membrane Potential Assay Kit (Abcam) according to the manufacturer's instructions. Cells treated with FCCP (carbonyl cyanide 4-((trifluoromethoxy)phenylhydrazine), an ionophore uncoupler of oxidative phosphorylation, were used as positive control for the loss of mitochondrial membrane potential.

Real-time PCR (RT-PCR). RNA was extracted from cells by the RNeasy Mini Kit (QiAGEN), and cDNA was synthesized using the High-Capacity RNA-to-cDNA Kit (Life Technologies), according to the manufacturer's instructions. For mRNA expression levels, RT-PCR assays were performed using human TaqMan probes for BCL2 (Hs00206023_m1), BCL2L1 (BCLX) (Hs0026229_m1), BCL2 f11 (BIM) (Hs0070819_1_s1), MCL1 (Hs00150986_m1), and human GAPDH endogenous control probe (4352934E, Life Technologies). Reactions were performed in triplicate on an ABI PRISM 7900HT platform (Life Technologies), and results were reported as the expression levels relative to the housekeeping gene in the same cells.

Generation of xenografts and in vivo drug treatments. All procedures involving animals, carried out under license PPL-70/7707, were performed in accordance with ARRIVE guidelines and National Home Office regulations under the Animals (Scientific Procedures) Act 1986 and reviewed by the Ethics Committee of Cancer Research UK Manchester Institute. Cancer Research UK Manchester Institute regulations under the Animals (Scientific Procedures) Act 1986 and reviewed by the Ethics Committee. Procedures involving animals, carried out under license PPL-70/7701, were performed in accordance with ARRIVE guidelines and National Home Office regulations under the Animals (Scientific Procedures) Act 1986 and reviewed by the Ethics Committee of Cancer Research UK Manchester Institute.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work was supported by the Kay Kendall Leukaemia Fund (KKL631) and Cancer Research UK (C15759/A12328). We thank Jane Rogan and Deepth Wilks for tissue collection; Lewis Woolley, Gemma Forrest, Adam Freestone, Lisa Bickley, Lisa Doar, Christopher Clark, and Tori Grady for general assistance; Jeff Barry and Helen Carlin for flow cytometry; Tim Somerville for normal CD34+ cDNA; Elena Galvani for help with calculating combination indices; Dr. Nicholas Donato (University of Michigan Ann Arbor, MI, USA) for BV173R cells; and Dr. Jihong Liu (Institute of Cancer Sciences, University of Manchester, UK) for SUP-B15R cells.

1. Hunger SP, Lu X, Devidas M, Carnotta BM, Gaynon PS, Winsk NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30: 1663–1669.
2. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology 2010; 2010: 21–29.
3. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381: 1943–1955.
4. Schultz KR, Bowman WP, Aledo A, Stacy WT, Sather H, Devidas M et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009; 27: 5157–5161.
5. Mukhopadhyay IG, Phillips LA, Su X, Miller CB, Miller DR, Shurtleff SA et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322: 1377–1380.
6. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Basecke J et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25: 1080–1094.
7. Irving J, Mehes E, Minto L, Haisel C et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014; 124: 3420–3430.
8. Perentes JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M et al. Ras oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 685–692.
9. Bonni A, Brunet A, West AE, Datta SR, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1997; 286: 1388–1362.
10. Luciano F, Jaccard A, Coirolocci P, Herraing M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785–6793.
11. Tse C, Shoemaker AR, Ackdiss J, Anderson MG, Chen J, Sin et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428.
12. Souers AJ, Levedson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.
13. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber PJ et al. Preclinical efficacy of ABT-263 in Nras-mutant AML. Blood 2014; 124: 3947–3955.
14. Egile A, Harris AW, Boulelt P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164–6169.
15. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Zabotar PE et al. Apoptosis initiated when B3 Igands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2004; 305: 856–859.
16. Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012; 119: 1726–1736.
17. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008, 112: 3807–3817.
18. Tsuchimoto Y, Finger UR, Yuris J, Nowell PC, Droce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097–1099.
19. Del Gaudio Moore V, Brown JR, Corto M, Love TM, Novina CD, Letal A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonists. J Clin Invest 2007; 117: 112–131.
20. Merino D, Khaw DL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2 and Bcl-xL are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemia cells. Blood 2012; 119: 5816–5827.
21. Lin X, Morgan-Lappe S, Huang X, Li L, Zwikels DM, Venneti LA et al. ‘Seed’ analysis of off-target smallRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-xL inhibitor ABT-737. Oncogene 2007; 26: 3972–3979.
22. van Delft MF, Wei AH, Mason KD, Vanden Berg J, Chen L, Zabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bax/Bak if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399.
23. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013; 23: 121–128.
24. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimic. J Clinical Invest 2008; 118: 3651–3659.

25. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408–2421.

26. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6: 443–450.

27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)